Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 2/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701444 | 0.83 | TACR1 (0.48) | POLBMEN1KMT2A | |
| SCHEMBL3035079 | 0.78 | CACNA1B (0.68) | RBP4CYP3A4GAACYP2C19LMNA | |
| SCHEMBL20864337 | 0.74 | IDO1 (0.43) | GAAMGLLMEN1KMT2A | |
| SCHEMBL12415412 | 0.74 | ALDH1A1 (0.41) | POLBSIGMAR1MEN1KMT2A | |
| SCHEMBL14701445 | 0.74 | SLC6A4 (0.54) | POLBSIGMAR1DCUN1D1MEN1KMT2A | |
| SCHEMBL13504041 | 0.74 | HPGD (0.70) | RBP4LMNAPOLBHPGDHSD11B1 | |
| SCHEMBL14701462 | 0.73 | TACR1 (0.49) | MEN1KMT2A | |
| SCHEMBL6208978 | 0.73 | HSD11B1 (0.84) | RBP4LMNAPOLBHPGDHSD11B1 | |
| SCHEMBL3455469 | 0.73 | ACHE (0.68) | LMNAHPGDHSD11B1MGLLSIGMAR1 | |
| SCHEMBL4779245 | 0.72 | SIGMAR1 (0.55) | CYP3A4GAACYP2C19LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | RBP4 1198/4885CYP3A4 939/4885GAA 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.